Clinical features and characteristics of pediatric patients with COVID-19 infection
Experiences in a Tertiary Taiwan Hospital

Geng-Hao Bai, MDa, Ping-Yi Shih, MDb, Shih-Yen Chen, MD, PhDc,d, Kai-Sheng Hsieh, MDd,e, Cheng-Che Chou, MDf, Po-Hao Feng, MD, PhDi, Shu-Sing Kong, MDg, Wen-Chuan Lin, MDh, Meng-Che Lu, MDih

Abstract
Coronavirus disease 2019 (COVID-19) patients have distinct clinical features in the pediatric groups. However, there is a paucity of research focused on clinical manifestation within pediatric group in Taiwan. This study is to conduct a retrospective study of the clinical features of COVID-19 in pediatric patients.

A retrospective study was conducted on pediatric patients (Aged ≤ 18 years) in a Northern Taiwan hospital from May 1st, 2021 to June 30th, 2021. Thirty-eight patients were included from emergency room. They were laboratory confirmed COVID-19 through specimens from nasopharyngeal swab by real-time reverse-transcription polymerase chain reaction (RT-PCR). Data including RT-PCR cycle threshold (Ct) values, clinical and epidemiological features were collected and analyzed.

Thirty-eight patients aged from 7-month to 18-year-old were included. The median age of patients was 15-year-old. The patients had sex ratio of 23 males to 15 females. More than half patients were infected from family members. Asymptomatic patients were 47.37%. In the symptomatic patients, fever (34.21%) was the most predominant symptom. Cough, nasal obstruction and sore throat were also common. Asymptomatic children had significantly higher Ct-values than symptomatic children, and diagnosed patients with Ct-values more than 19 were associated with asymptomatic infection (P = .0084).

Ct-values higher than 19 were associated with asymptomatic infection, which may be a predictor of pediatric disease severity. Our results highlight the distinct clinical manifestations and outcomes in pediatric COVID-19 patients. Compared to the adults, pediatric patients aged ≤ 18 years with COVID-19 in Taiwan mainly had mild disease.

Abbreviations: COVID-19 = coronavirus disease 2019, Ct = cycle threshold, RT-PCR = real-time reverse-transcription polymerase chain reaction, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Keyword: covid-19, pediatrics, symptomatic, viral load

1. Introduction
Coronavirus disease 2019 (COVID-19) firstly appeared in Wuhan, China during December 2019.[1] This ongoing pandemic disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and now has spread around the world.[2] Many COVID-19 patients especially in adults develop pneumonia, acute respiratory distress syndrome or multiple organ failure rapidly.[3-5] However, literature in different countries reveal that pediatric COVID-19 patients have distinct clinical features comparing to the adult groups.[6-15] Though some studies notice increased risk in infants and adolescent groups, most of the children with COVID-19 infection only get mild symptoms.[11-15] The most common symptoms in children are
fever and cough. Including pediatric multisystem inflammatory syndrome, severe illness in the pediatric groups is around 1–6%. Because most of the pediatric COVID-19 patients have mild symptoms and less frequency of exposure to some sources of transmission, testing for diagnosis is less frequent. Real-world clinical and epidemiological data in pediatric groups may be understated. Due to the Taiwan government’s early and appropriate measures, incidences of newly confirmed COVID-19 cases are relatively low. Even though real-world research focused on initial clinical manifestation within pediatric group in Taiwan has been published, the relation of viral load between asymptomatic and symptomatic group should be further explored. Therefore, the aim of this research is to conduct a retrospective study not only to identify the clinical features and characteristics of COVID-19 in Taiwan pediatric patients but also to investigate the viral load in our pediatric patients who were asymptomatic or mild disease.

2. Methods
We conducted a retrospective chart review study at Taipei Medical University Shuang Ho Hospital, Ministry of Health and Welfare in New Taipei City, Taiwan. The chart review period was from May 1 to June 30, 2021. We included pediatric patients (aged 0–18 years) with laboratory confirmed COVID-19 infection. The COVID-19 infection was diagnosed and confirmed by real-time reverse-transcription polymerase chain reaction (RT-PCR). All the patients received real-time RT-PCR test at our emergency department, screening station or at the time of admission. The samples were taken from upper nasopharyngeal swabs. The diagnostic definition of COVID-19 was based on guidelines issued by the Taiwan Centers for Disease Control.

Since the wide effort to increase testing, SARS-CoV-2 testing has been offered at select primary care sites including Shuang Ho Hospital emergency department to all patients with suspected SARS-CoV-2 exposures regardless of symptoms. A positive result on RT-PCR was defined to a confirmed case. For children tested more than once only their first-time positive RT-PCR results were included in this study. We screened all the confirmed cases and collected relevant new onset clinical data through electronic medical record, including gender, age, symptoms, cycle threshold (Ct) value while diagnosed, laboratory hemogram and biochemistry data, image study and treatments. Epidemiological investigation was focused on the possible route of transmission and the contact history. BD MAX System (Becton, Dickinson and Company) was used as RT-PCR platform. RT-PCR reagent kit targeted RNA from the nucleocapsid phosphoprotein gene (N1 and N2 regions) of the SARS-CoV-2 coronavirus, and the human RNase P gene.

Disease severity in this article was decided by whether the included patients were asymptomatic or symptomatic. Children were determined to be symptomatic when they had newly onset symptoms within 7 days prior to positive RT-PCR test at our emergency department related to COVID-19, including fever, cough, nasal discharge, sore throat, diarrhea, myalgia, headache, and dysosmia. Asymptomatic children were determined by no symptoms that mentioned above documented at our emergency department. Patients were divided into 2 groups according to age; one was younger than 12 years old and the other was from 12 to 18 years old. Respiratory symptoms in this article were defined as children with cough, nasal obstruction or sore throat. Ct-values were compared in regard to disease severity, age, and respiratory symptoms.

We searched PubMed for previous similar studies published from their inception until January 2022. A combination of subject headings and text words was used for the literature search: (1) COVID-19 or SARS-CoV-2 and (2) Pediatric or Children or Adolescent and (3) Ct-value or Viral load and (4) Asymptomatic or Symptomatic. The summary of comparison Ct-value between asymptomatic and symptomatic patients in previous studies was presented at Table 3 which also included author, year, country, study period, median or mean age, type of swabs, and Ct-value in 2 groups.

This study has been approved by expedited review process of the ethics committee Taipei Medical University Joints Institutional Review Board in the meeting #110-08-3 with approval number N202108049 and followed the Declaration of Helsinki.

2.1. Statistical analysis
Two-sample test for equality of proportion was used to examine the demographic features between asymptomatic and symptomatic groups. A Student t test and Wilcoxon-Mann-Whitney test were used to compare Ct-value between the groups including disease severity, age, and respiratory symptoms. Fisher exact tests and 2 by 2 tables were used to assess the cutoff point of Ct-value for symptomatic patients. Means with standard deviation (SD) and median with interquartile range (IQR) of clinical data were reported in tables. Statistical tests were 2-sided and a P value < 0.05 was determined statistically significant. The statistical calculations were performed through SPSS (Inc. Released 2009. PASW Statistics for Windows, Version 18.0. Chicago: SPSS Inc.)

3. Result
Thirty-eight patients aged from 7-month to 18-year-old were positive for SARS-CoV-2 by PCR at our hospital during the study period. The median age of patients was 15 years old with interquartile range (12–16 years old). The patients had sex ratio of 23 males to 15 females. More than half patients (63.2%) were infected from family members with COVID-19. All the included children were either asymptomatic or presented with mild symptoms, and almost half (47.4%) of them were asymptomatic. Only 3 patients (7.9%) need hospital admission for care problem because all family members were isolated (Table 1).

Among 20 symptomatic patients, fever (65%) was the most predominant symptom. Respiratory symptoms such as cough (50%), nasal obstruction or discharge (50%), and sore throat (35%) were also common. Few patients developed diarrhea, myalgia, headache, and dysosmia. There was no dyspnea, desaturation, critically ill or death in the included patients (Table 1).

Comparing demographic features between asymptomatic and symptomatic patients, neither sex ratio or median age was significantly different between 2 groups. Interestingly, patients who

| Characteristic | No (%) |
|----------------|--------|
| Age, yr, median (IQR) | 15 (12–16) |
| Sex | |
| Female, n (%) | 15 (39.5) |
| Male, n (%) | 23 (60.5) |
| Household transmission, n (%) | 24 (63.2) |
| Clinical symptoms | |
| Asymptomatic, n (%) | 18 (47.4) |
| Mild symptomatic, n (%) | 20 (52.6) |
| Fever | 13 (65) |
| Cough | 10 (50) |
| Nasal discharge | 10 (50) |
| Sore throat | 7 (33) |
| Diarrhea | 3 (15) |
| Myalgia | 2 (10) |
| Headache | 2 (10) |
| Dysosmia | 1 (5) |
| Admission rate, n (%) | 3 (7.9) |
were younger than 12 years old were almost in symptomatic group (87.5%). Moreover, children who were transmitted by their family were significantly more in symptomatic group than asymptomatic group ($P = .023$). Furthermore, using Fisher exact test, we found that newly diagnosed patients with Ct-values $>19$ was highly associated with asymptomatic infection ($P = .0084$) (Table 2).

The mean Ct-value of symptomatic children ($16.65 \pm 5.61$) was significantly lower than asymptomatic children ($22.61 \pm 7.07$) ($P = .006; 95\% CI = 1.78–10.14$) (Fig. 1). In regard to different age group, the mean Ct-value did not show significant difference between patients younger and older than 12 years old (Fig. 1). Children with respiratory symptoms including cough, nasal obstruction, and sore throat had significantly lower men Ct-value than the children without those symptoms ($P = .014; 95\% CI = 1.86–14.65$).

Table 3 presented the summary of 14 previous studies that compared Ct-value or viral loads between asymptomatic and symptomatic children. Eight studies were from United States, another 3 studies were from Europe and the others were from Asia. The samples were mostly from nasopharyngeal swabs. Over 70% of studies showed symptomatic children had higher viral loads (lower Ct-value) than asymptomatic children, and only 4 studies presented no significant difference between 2 groups. The correlation between age and Ct-value was varied among the included studies. Some of them showed younger children had lower Ct-value; however, the others showed no difference among different age groups. Two of the included studies investigated the relation between presented symptoms and viral loads, one showed no difference, the other presented children with cough or sputum production had lower Ct-value.

4. Discussion

This study revealed more than half patients were household transmission. This finding is consistent with several observational studies and literature reviews which pointed out children are more likely to contract virus from adult household members. Moreover, the clinical features of the disease were mild in this study and almost one-half patients were asymptomatic. The asymptomatic rate of the patients was slightly higher than most of systematic reviews had reported; however, the asymptomatic rate was the same as the study of pediatric group in Taiwan. This study revealed fever and cough as the most typical manifestations in symptomatic patients. This finding was similar to the pooled results from the systematic reviews. In addition to respiratory symptoms, few patients developed gastrointestinal or neurological symptoms in this study. Symptomatic children were more significantly transmitted by their family. The result was in contrast to Ustundag et al which revealed household contact didn't have significant effect on the presence of symptoms.

We also investigated the correlation of viral loads in regard to disease severity, age, and respiratory symptoms. We observed that asymptomatic children had significantly higher Ct-value than symptomatic children. Ct-values higher than 19 were associated with asymptomatic infection which may be a predictor of disease severity. This finding was similar to the data reported by several studies which indicated symptomatic children may have a higher viral load in the nasopharynx than asymptomatic children. However, the data from Chu et al, Ford et al, Hurst et al, and Peaper et al showed no significant difference in viral load between symptomatic and asymptomatic children. The results might be related to the number of infected children and the bias toward inclusion of symptomatic children in the study.

No significant difference of Ct-value was observed between younger and older groups. It was in contrast to the findings of Strutner et al and Pinninti et al, the studies pointed out compared to other age groups, Ct-Value was significantly lower in age $< 5$ years old and significantly lower in age $< 1$ years old, respectively. The reasons might be that children from 1 year old
Table 3

| Author year | Country         | Study period | Age               | Swab       | Target gene | Asymptomatic | Symptomatic | Asymptomatic | Symptomatic | P    | Asymptomatic viral load | Symptomatic viral load | Ct-Value outcome summary | Reference |
|-------------|-----------------|--------------|-------------------|------------|-------------|--------------|-------------|--------------|-------------|------|------------------------|------------------------|------------------------|-----------|
| Chu 2021    | Korea           | February 18–April 30, 2020 | Mean (range) 9.8 (1–18) | NP         | RdRp E gene N gene | 13 E: 30.3 [28.3–32.2] RdRp: 33.0 [31.3–35.0] N: 34.8 [32.1–37.2] | 18 E: 31.8 [29.5–34.3] RdRp: 34.2 [32.0–36.0] N: 35.1 [33.1–37.0] | 0.49 | 0.33 | 0.63 | Symptomatic and asymptomatic: No difference | | | [1] |
| Chua 2021   | Hong Kong       | March 12–August 8, 2020 | NP or Saliva 8.6 [4.3–11.0] 9.2 [4.0–15.0] | NP         | RdRp E gene N gene | 63 E: 5.7 [4.3–7.4] Saliva: 4.5 [3.6–5.1] [Mean log RNA] | N: 6.8 [5.6–8.3] Saliva: 5.8 [4.9–6.7] [Mean log RNA] | <0.001 | Saliva: <0.001 | Symptomatic < asymptomatic | With (Cough, sputum or headache); Lower Saliva | | [2] |
| Chung 2021  | USA             | March 23–November 9, 2020 | 7.5 (5.3) | MTB or AN | S gene | 76 N/A Mean difference −3.0, 95% CI (−5.5 to −0.6) | 51 N/A | 0.004 | Symptomatic < asymptomatic | | Adults and Children: No difference | | [4] |
| Cotugno 2021| Italy           | March–July, 2020 | AS: 4.8 (3.4–5.6) 5–8 yrs | NP         | RdRp E gene N gene | 15 N/A | N/A | N/A | N/A | Symptomatic and asymptomatic: No difference | | | [5] |
| Ford 2021   | USA             | November 16–December 15, 2020 | 9–12 yrs | AN | ORF1ab S gene | 18 N: 22.2 [21.6–31.6] | 24 N: 24.3 [21.4–27.3] | N/A | Symptomatic and asymptomatic: No difference | | | | [7] |
| Ford 2021   | USA             | November 16–December 15, 2020 | 11.8 [9.0–14.3] | NP | RdRp E gene N gene | 30 N/A | 4.1 [1.9] [Mean log RNA] | 89 5.9 (1.8) [Mean log RNA] | <0.001 | Symptomatic < asymptomatic | | | [8] |
| Huillier 2021| Switzerland    | November 10–March 26, 2021 | 10.4 [4.8–16.4] | NP or MTB | E gene N gene | 52 3.8 [2.8–6.3] | 126 4.1 [3.0–5.5] | 0.56 | Symptomatic < asymptomatic | | | | [9] |
| Kam 2021    | Singapore       | March 23–April 5, 2020 | 7.7 [0.3–15.8] | NP | E gene | 7 36.7 | 10 28.6 | 0.02 | Symptomatic < asymptomatic | | | | [10] |
| Kocijek 2021| USA             | March–July, 2020 | N/A | NP or oropharyngeal | N/A | 339 Adjusted: 8.6 [2.5–12.2] | 478 Adjusted: 1.7 [6.0–4.8] | < 0.0001 | Symptomatic < asymptomatic | | | | [11] |
| Ollier 2022 | France          | January 15–May 28, 2021 | 1.7 [0.4–5.2] | NP | RdRp E gene N gene | 11 N: 29.8 (8.5) RdRp: 29.2 (8.0) | 35 N: 22.2 (5.8) RdRp: 22.7 (5.5) | 0.002 | 0.005 | Symptomatic < asymptomatic | | | | [12] |
| Peaper 2020 | USA             | March 1–September 26, 2020 | 12.0 [5.0–16.0] | NP or MTB | N gene | 38 N/A | 44 N/A | N/A | N/A | Symptomatic and asymptomatic: No difference | | | | [13] |
| Pinninti 2021| USA            | March 24–August 20, 2020 | 9.78 [6.56] | NP, nasal, saliva, or rectal | N gene | 45 34 (median) | 57 26 (median) | 0.001 | Symptomatic and asymptomatic: No difference | | | | [14] |
| Strutner 2021| USA            | April 1–August 1, 2020 | 7.5 [2.0–14.0] | AN or NP | ORF1ab S gene N1&N2 gene | 210 ORF1ab S gene N1&N2 gene | 518 ORF1ab S gene N1&N2 gene | 19.9 (6.3) | <0.001 | Symptomatic < asymptomatic | | | | [15] |
| Zachariah 2020| USA            | March 14–April 24, 2021 | Infants and 1–21 yrs old | NP | E gene | N/A | N/A | N/A | N/A | Symptomatic infants: Higher viral load | | | | [16] |

Ct, Cycle threshold; AN, Anterior nares; MTB, Middle turbinate; NP, Nasopharyngeal; SD, Standard deviation; IQR, interquartile range; N/A, not applicable; E, envelope; RdRp, RNA-dependent RNA polymerase; N, nucleocapsid; S, spike glycoprotein; ORF1ab, open reading frame 1ab.
to 11 years old were not presented at our hospital, and also the small sample size might lead to no significant results. Among mild symptomatic children, children with respiratory symptoms had significant lower mean Ct-Value than children without respiratory symptoms. Due to the small sample sizes, it cannot come to a conclusion. However, the pathophysiology of virus invasion may explain the finding, when increased amount of the virus migrated from the nasal epithelium to the upper respiratory tract, the involvement of the upper airways may present with respiratory symptoms of dry cough.[49] Further studies in the future can investigate the possible factors that may influence the viral loads measured from infected children such as RNA extraction kit, rrt-PCR assay, targeted gene, the time points of the diseases and the variants of SARS-CoV-2.

To date, the Omicron variant is the most rapidly transmitted SARS-CoV-2 variant. In the United States, till February 02/12/2022, Omicron variant is the dominant variant with 3 common lineages, BA.1.1, B.1.1.529, and BA.2. BA.1.1 accounts for 73.2% of the total cases infected with SARS-CoV-2.[49] Although a preprint study revealed the emergence of the Omicron variant in the United States was associated with significantly milder disease in the early phase of infection as compared to the Delta variant period,[50] researchers from Denmark found that Omicron is about 2.7–3.7 times more infectious than Delta among vaccinated individuals.[51] A retrospective cohort study of electronic health record data pointed out the less severe outcome for the infected children under age 5 during Omicron predominated period than during Delta variant predominated.[52] However, nowadays, there was no enough evidence of clinical presentation in children with the Omicron variant. Pediatric acute upper airway infection cases have increased during the Omicron variant surge and nearly a third of affected children develop severe disease.[53] Croup, one of the most severe manifestations of upper respiratory infections in children has been reported a sharp rise in cases during this period.[54] Therefore, in order to prevent this highly contagious variant and the severe upper airway infection, it is important for preventive measures including increasing the rate of vaccinations, universal masking in schools, other indoor public spaces and child care centers.[55,56] There were several limitations in our study. First, it was a retrospective and single-center study. Second, generalizability was limited by the small sample size of this study. Next, the inconsistency of the record from emergency department may lead to incomplete information. Moreover, symptoms are reported by patients themselves, and children may not be able to clearly describe their symptoms. Finally, the Ct-values were collected when children presented at our hospital; thus, the various time points of the infection diseases may affect the result of viral load.

5. Conclusion
Ct-values higher than 19 were associated with asymptomatic infection, which may be a predictor of pediatric disease severity. Asymptomatic children had significantly higher mean Ct-value than symptomatic children. Household transmission of asymptomatic children with COVID-19 infection should be more closely guarded. Fever and cough were prevalent symptoms in children with SARS-CoV-2 infection. Further studies should recruit larger sample sizes and assess the pathophysiology of the difference between asymptomatic and symptomatic children.

Author contributions
All the research team designed and conducted the research. GHB and PYS analyzed the data. GHB, PYS, and MCL wrote the article. GHB, PYS, and MCL had primary responsibility for final content.

References
[1] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.
[2] World Health Organization. WHO: Coronavirus disease 2019 (COVID-19): situation dashboard. Available at: https://covid19.who.int [access date February 20, 2022].
[3] Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.
[4] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
[5] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–81.
[6] Tian S, Hu N, Lou J, et al. Characteristics of COVID-19 infection in Beijing. J Infect. 2020;80:401–6.
[7] Parri N, Lenge M, Buonsenso D, Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group. Children with Covid-19 in pediatric emergency departments in Italy. N Engl J Med. 2020;383:187–90.
[8] Tagarro A, Epalza C, Santos M, et al. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr. 2020;174:1009.
[9] Team CC-R. Coronavirus disease 2019 in children—United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:422–6.
[10] Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323:2052–9.
[11] Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145:e20200702.
[12] Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020;382:1663–5.
[13] Qu H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020;20:689–96.
[14] Jiehao C, Jin X, Daqiong L, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020;71:e1–e9.
[15] Zachariah P, Johnson CL, Halabi KC, et al. Epidemiological features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children’s hospital in New York City, New York. JAMA Pediatr. 2020;174:e202430.e202430.
[16] Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). Available at: https://www.cdc.gov/mis-c [access date February 20, 2022].
[17] Robinson J, Freire D. COVID-19—What does a paediatrician need to know? Paediatr Respir Rev. 2020;35:3–8.
[18] Zeng L, Xia S, Yuan W, et al. Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. JAMA Pediatr. 2020;174:71–7.
[19] Liguoro I, Pilotto C, Bonanni M, et al. SARS-COV-2 infection in newborns: a systematic review. Eur J Pediatr. 2020;179:1029–46.
[20] Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020;39:355–68.
[21] Taiwan Centers for Disease Control. Weekly Number of Suspected COVID-19 Cases Reported—By Sources. Available at: https://www.cdc.gov.tw/En [access date February 20, 2022].
[22] Sim JY, Wu PS, Cheng CF, et al. Characteristics, contacts, and relative risk of SARS-CoV-2 infection among children during school closures (published online ahead of print December 31, 2021). J Microbiol Immunol Infect. doi: 10.1016/j.jmii.2021.12.004.
[23] Taiwan Centers for Disease Control. Recommendations for COVID-19: Case definition, specimen collection, and diagnostic tests. Available at: https://www.cdc.gov.tw/Files/Get/ZqfUSkCMvTAy579T0AYQ [access date February 20, 2022].
[24] Strunz T, Ramchandani N, Dubey S, et al. Comparison of reverse-transcription polymerase chain reaction cycle threshold values from respiratory specimens in symptomatic and asymptomatic children with severe acute respiratory syndrome coronavirus 2 infection. Clin Infect Dis. 2021;73:1790–4.
[25] Chua GT, Wong JSC, To KKW, et al. Saliva viral load better correlates with clinical and immunological profiles in children with coronavirus disease 2019. Emerg Microbes Infect. 2021;10:235–41.
26. Chu MA, Jang YY, Lee DW, et al. Viral load and rebound in children with coronavirus disease 2019 during the first outbreak in Daegu city. Clin Exp Pediatr. 2021;64:e652–60.

27. Chung E, Chow EJ, Wilcox NC, et al. Comparison of symptoms and RNA levels in children and adults with SARS-CoV-2 infection in the community setting. JAMA Pediatr. 2021;175:e212025.

28. Cotugno N, Ruggiero A, Pascucci GR, et al. Virological and immunological features of SARS-CoV-2 infected children with distinct symptomatology. Pediatr Allergy Immunol. 2021;32:1833–42.

29. Ford L, Whaley MJ, Shah MM, et al. Antigen test performance among children and adults at a SARS-CoV-2 community testing site. J Pediatr Infect Dis Soc. 2021;10:1052–61.

30. L'Huillier AG, Lacour M, Sadiku D, et al. Diagnostic accuracy of SARS-CoV-2 rapid antigen detection testing in symptomatic and asymptomatic children in the clinical setting. J Clin Microbiol. 2021;59:e0099121.

31. Hurst JH, Heston SM, Chambers HN, et al. SARS-CoV-2 infections among children in the biospecimens from respiratory virus-exposed kids (BRAVE Kids) study. medRxiv. 2020.

32. Kam KQ, Thoon KC, Mawald M, et al. SARS-CoV-2 viral RNA load dynamics in the nasopharynx of infected children. Epidemiol Infect. 2021;149:e18.

33. Kociolek LK, Muller WJ, Yee R, et al. Comparison of upper respiratory viral load distributions in asymptomatic and symptomatic children diagnosed with SARS-CoV-2 infection in pediatric hospital testing programs. J Clin Microbiol. 2020;58:e02593–20.

34. Ollier Q, Pillet S, Mory O, et al. Prospective evaluation of the point-of-care use of a rapid antigen SARS-CoV-2 immunochromatographic test in a paediatric emergency department. Clin Microbiol Infect. 2022;28:734.e1–e6.

35. Peaper DR, Murdock C, Oliveira CR, et al. Severe acute respiratory syndrome coronavirus 2 testing in children in a large regional US health system during the coronavirus disease 2019 pandemic. Pediatr Infect Dis J. 2021;40:175–81.

36. Pinotti SG, Pati S, Poole C, et al. Virological characteristics of hospitalized children with SARS-CoV-2 infection. Pediatrics. 2021;147:e2020037812.

37. Soriano-Andares A, Gatell A, Serrano P, et al. Household severe acute respiratory syndrome coronavirus 2 transmission and children: a network prospective study. Clin Infect Dis. 2021;73:e1261–9.

38. Ng DC, Tan KK, Chin L, et al. Clinical and epidemiological characteristics of children with COVID-19 in Negeri Sembilan, Malaysia. Int J Infect Dis. 2021;108:347–52.

39. Ustundag G, Yilmaz-Ciftdogan D, Kara-Aksay A, et al. COVID-19 in healthy children: What is the effect of household contact? Pediatr Int. 2021;64:e14890.

40. Katsuta T, Shimizu N, Okada K, et al. The clinical characteristics of pediatric coronavirus disease 2019 in 2020 in Japan. Pediatr Int. 2021;64:e14912.

41. Siebach MK, Predimonte G, Leye SH. COVID-19 in childhood: transmission, clinical presentation, complications and risk factors. Pediatr Pulmonol. 2021;56:1342–56.

42. Cui X, Zhao Z, Zhang T, et al. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). J Med Virol. 2021;93:1057–69.

43. Badal S, Thapa Bagajin K, Badal S, et al. Prevalence, clinical characteristics, and outcomes of pediatric COVID-19: a systematic review and meta-analysis. J Clin Virol. 2021;135:104715.

44. Qi K, Zeng W, Ye M, et al. Clinical, laboratory, and imaging features of pediatric COVID-19: a systematic review and meta-analysis. Medicine (Baltim). 2021;100:e25230.

45. Taheri L, Gheiasi SF, Taher M, et al. Clinical features of COVID-19 in newborns, infants, and children: a systematic review and meta-analysis [published online ahead of print June 14, 2021]. Compr Child Adolesc Nurs. doi: 10.1080/24694193.2021.1930288.

46. Song WL, Zou N, Guan WH, et al. Clinical characteristics of COVID-19 in family clusters: a systematic review. World J Pediatr. 2021;17:355–63.

47. Yasuhara J, Kuno T, Takagi H, et al. Clinical characteristics of COVID-19 in children: a systematic review. Pediatr Pulmonol. 2020;55:2565–75.

48. Parasher A. COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021;97:312–20.

49. Centers for Disease Control and Prevention. COVID Data Tracker. Available at: https://covid.cdc.gov/covid-data-tracker/#variant-proportions [access date February 20, 2022].

50. Wang L, Berger NA, Kaebler DC, et al. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. medRxiv. Preprint posted online January 2, 2022. doi:10.1101/2021.12.30.21268495.

51. Lynge FP, Mortensen LH, Denwood MJ, et al. SARS-CoV-2 Omicron VOC Transmission in Danish Households. medRxiv. 2021;12.27.21268278.

52. Wang L, Berger NA, Kaebler DC, et al. COVID infection severity in children under 5 years old before and after Omicron emergence in the US, medRxiv. Preprint posted online January 13, 2022. doi:10.1101/2022.01.12.22269179.

53. Martin B, DeWitt PE, Russell S, et al. Acute upper airway disease in children with the omicron (B.1.1.529) variant of SARS-CoV-2: a report from the US National COVID cohort collaborative. JAMA Pediatr. 2022;176:819–21.

54. Tunç EM, Shin CKJ, Usoro E, et al. Group during the COVID-19 Omicron Variant Surge. medRxiv. 2022;2022.02.02.22270222.

55. Hause AM, Baggs J, Marquez P, et al. COVID-19 vaccine safety in children aged 5-11 years - United States, November 3-December 19, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1755–60.

56. Delahoy MJ, Ujamaa D, Whitaker M, et al. Hospitalizations associated with COVID-19 among children and adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1255–60.